References
- Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstructive Surg 2006;117:286–300.
- Faltoaizpurua L, Abyaneh MY, Griffith RD, Nouri K. Cells to surgery quiz: July 2014. Hypertrophic scar. J Invest Dermatol 2014;134:e3.
- Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner, GC, Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2011;17763–771.
- Thompson CM, Hocking AM, Honari S, Muffley LA, Ga M, Gibran NS. Genetic risk factors for hypertrophic scar development. J Burn Care Res Off Publ Am Burn Assoc 2012;34:477–482.
- Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatrics 2006;18:396–402.
- Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res 2010;302:319–339.
- He L, Weber A, Levens D. Nuclear targeting determinants of the far upstream element binding protein, a c-Myc transcription factor. Nucleic Acids Res 2000;28:4558–4565.
- Thornberry NA, Lazebnik Y. Caspases: enemies Within. Science 1998;281:1312–1316.
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479–489.
- Gao J, Chen Y, Liao N, Zhao W, Zeng W, Yingtao LI, Wang, S, Feng LU. Relationship between p53 gene codon-72 polymorphisms and hypertrophic scar formation following caesarean section. Exp Ther Med 2014;7:1243–1246.
- Ray S, Ju X, Sun H, Finnerty CC, Herndon DN, Brasier AR. The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar. J Invest Dermatol 2013;133:1212–1220.
- Sidgwick GP, Bayat A. Extracellular matrix molecules implicated in hypertrophic and keloid scarring. J Eur Acad Dermatol Venereol Jeadv 201226:141–152.
- Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R. C-MYC is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151:68–79.
- Depinho RA, Schreiber-Agus N, Alt FW. MYC family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991;57:1–46.
- He L, Liu J, Collins I, Sanford S, O’Connell B, Benham CJ, Levens D. Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. Embo J 2000;19:1034–1044.
- del Olmo ML, Sogo JM, Franco L, Pérezortín JE. Chromatin structure of the yeast FBP1 gene: transcription-dependent changes in the regulatory and coding regions. Yeast 1993;9:1229–1240.
- Liu J, Kouzine F, Nie Z, Chung H‐J, Elisha‐Feil Z, Weber A, Zhao K, Levens D. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c‐myc expression. Embo J 25:2006;2119–2130.
- Zaman S, Sukhodolets K, Wang P, Qin J, Levens D, Agarwal SK, Marx SJ. FBP1 is an interacting partner of Menin. Int J Endocrinol 2014;535401–535401.
- Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005;25:147–161.